Latest news with #NovartisPharmaceuticalsCanadaInc
Yahoo
10-07-2025
- Health
- Yahoo
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS) Following this important milestone, Cosentyx has been listed in Québec MONTRÉAL, July 10, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx (secukinumab) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS), a chronic, painful and often debilitating inflammatory skin condition.1 Following the completion of these negotiations, Cosentyx has been listed in Québec, making it the first province to provide public reimbursement for Cosentyx in HS. Novartis remains committed to ongoing collaboration with provincial public drug programs across Canada to enable timely access and reimbursement for eligible patients nationwide. "Too often, people living with HS feel like their condition is invisible within the healthcare system," said Latoya Palmer, Founder of Hidradenitis and Me Support Group. "As someone living with HS, it gives me hope to see this step forward. It feels validating and shows people like me that there is a path toward better support for those who need it most." "For people living with moderate to severe HS, the condition can have a profound impact on daily life - not only due to physical symptoms, but also the emotional toll it can take," said Dr. Susan Poelman, Canadian and U.S. Board-Certified Dermatologist. "The conclusion of pCPA negotiations for Cosentyx is a promising step that could help expand possibilities for patients who have historically had limited treatment options." "Concluding pCPA negotiations for Cosentyx in HS is an important step toward improving access to a therapy grounded in strong science and real patient need," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "At Novartis, we are committed to continuing to work with stakeholders across the healthcare system to help ensure eligible patients with HS have timely public access to innovative treatment options." About Cosentyx® (secukinumab) Cosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in many inflammatory diseases.2,3 Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), Axial spondyloarthritis (axSpA) and juvenile idiopathic arthritis (JIA).4,5,6,7,8,9 These data strengthen the position of Cosentyx as a treatment across moderate to severe PsO (adult and pediatric), PsA, HS, axial spondyloarthritis (axSpA), and juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis and juvenile PsA. More than 1 million patients have been treated with Cosentyx worldwide since its launch in 2015. About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit FA-11466794E_________________________________1 Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Accessed on June 6, 2025. Available at: Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167: 717-724. Accessed on June 6, 2025. Available at: Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 2019; 5: e001005.5 Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507-1514.6 Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol 2020; 2: 18-25.7 Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.8 Data on file. CAIN457F2312 (FUTURE 2): 5 year-interim report. Novartis Pharmaceuticals Corp; May 2019.9 McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1137-1146. SOURCE Novartis Pharmaceuticals Canada Inc. View original content to download multimedia:
Cision Canada
10-07-2025
- Health
- Cision Canada
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) Français
Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS) Following this important milestone, Cosentyx has been listed in Québec MONTRÉAL, July 10, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx (secukinumab) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS), a chronic, painful and often debilitating inflammatory skin condition. 1 Following the completion of these negotiations, Cosentyx has been listed in Québec, making it the first province to provide public reimbursement for Cosentyx in HS. Novartis remains committed to ongoing collaboration with provincial public drug programs across Canada to enable timely access and reimbursement for eligible patients nationwide. "Too often, people living with HS feel like their condition is invisible within the healthcare system," said Latoya Palmer, Founder of Hidradenitis and Me Support Group. "As someone living with HS, it gives me hope to see this step forward. It feels validating and shows people like me that there is a path toward better support for those who need it most." "For people living with moderate to severe HS, the condition can have a profound impact on daily life - not only due to physical symptoms, but also the emotional toll it can take," said Dr. Susan Poelman, Canadian and U.S. Board-Certified Dermatologist. "The conclusion of pCPA negotiations for Cosentyx is a promising step that could help expand possibilities for patients who have historically had limited treatment options." "Concluding pCPA negotiations for Cosentyx in HS is an important step toward improving access to a therapy grounded in strong science and real patient need," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "At Novartis, we are committed to continuing to work with stakeholders across the healthcare system to help ensure eligible patients with HS have timely public access to innovative treatment options." About Cosentyx ® (secukinumab) Cosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in many inflammatory diseases. 2,3 Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), Axial spondyloarthritis (axSpA) and juvenile idiopathic arthritis (JIA). 4,5,6,7,8,9 These data strengthen the position of Cosentyx as a treatment across moderate to severe PsO (adult and pediatric), PsA, HS, axial spondyloarthritis (axSpA), and juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis and juvenile PsA. More than 1 million patients have been treated with Cosentyx worldwide since its launch in 2015. About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit FA-11466794E SOURCE Novartis Pharmaceuticals Canada Inc.
Cision Canada
03-07-2025
- Business
- Cision Canada
Quebec implements public reimbursement of Pluvicto® - a defining milestone for radioligand therapy in Canada Français
Pluvicto ® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as more jurisdictions recognize radioligand as a critical therapy for advanced prostate cancer MONTREAL, July 3, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto ® (lutetium (177 Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). This new funding milestone marks a significant expansion in access to this innovative radioligand therapy. With reimbursement now secured in Quebec, Pluvicto ® is publicly funded in the country's four most populous provinces, bringing new treatment opportunities to Canadians living with PSMA-positive mCRPC who have previously undergone androgen receptor pathway inhibition and taxane-based chemotherapy. "We have been looking forward to this day for some time now as it represents a significant breakthrough for people in Quebec who have been longing for access to this much-needed treatment," said Laurent Proulx, President and CEO of PROCURE. "This progress brings real hope to countless patients and highlights how vital it is to make cutting-edge therapies available across Canada. We urge all provinces to keep moving forward so that every eligible patient, no matter where they live, can benefit from the best possible care and quality of life." Reimbursement in Quebec gives physicians more flexibility to integrate radioligand therapy into the treatment path for appropriate patients with advanced disease. "Public reimbursement of Pluvicto ® in Quebec is a meaningful advancement for individuals with PSMA-positive mCRPC who have already undergone multiple lines of treatment," said Dr. Frédéric Arsenault, President, Association des médecins spécialistes en médecine nucléaire du Québec. "Expanding access to radioligand therapy, a growing pillar in cancer care, marks a shift toward a new era of precision treatment that reflects the rapidly advancing oncology landscape. This decision helps close a longstanding treatment gap and will allow patients to receive timely treatment and care that offers hope and the potential to improve quality of life 1." Pluvicto ® is now publicly reimbursed in seven provinces: Quebec, Ontario, Alberta, British Columbia, Nova Scotia, Saskatchewan, and Newfoundland and Labrador. Each provincial listing extends access to more patients across the country and signals growing recognition of radioligand therapy as an important addition to advanced prostate cancer treatment options. "This announcement adds to the growing momentum behind the adoption of Pluvicto ® and radioligand therapy in prostate cancer care," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "It sends a strong signal that this approach is being recognized as a key part of the evolving cancer treatment landscape. We'll continue working closely with other jurisdictions to maintain this progress and help ensure every eligible patient across the country can access this important treatment option." Approved by Health Canada in August 2022, Pluvicto ® is the first targeted radioligand therapy for the treatment of PSMA-positive mCRPC in Canada 2. About Pluvicto ® Pluvicto ® (lutetium (177 Lu) vipivotide tetraxetan injection) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy 2. It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle) 2. After administration into the bloodstream, Pluvicto ® binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein 2. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells disrupting their ability to replicate and/or triggering cell death 2. About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit Pluvicto is a registered trademark. SOURCE Novartis Pharmaceuticals Canada Inc.
